High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases by Schönholzer, Carlo et al.
Nephrol Dial Transplant (2004) 19: 2121–2125
DOI: 10.1093/ndt/gfh307
Brief Report
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Abstract
Background. Pure red-cell aplasia (PRCA) after eryth-
ropoietin (Epo) administration due to the appearance
of neutralizing anti-Epo antibodies has been reported
in over 200 cases between 1998 and 2002. However,
large intercountry disparities were observed in the
occurrence of this syndrome.
Methods. On behalf of the Swiss Society of
Nephrology, a survey was conducted in all the dialysis
units of Switzerland in order to collect information
on the occurrence, diagnostic and evolution data of
the cases observed. A questionnaire was send to the
nephrologists in charge of each of the 69 dialysis
units in January 2003. The clinical and biological data
of the suspected cases were analysed and compared
with the data provided to health authorities and
pharmaceutical companies.
Results. A total of ﬁve cases were identiﬁed as true
PRCA with demonstrated positive anti-Epo anti-
bodies. They occurred between November 1998 and
February 2002, were all treated by haemodialysis and
had received Epo subcutaneously. The median appear-
ance time of refractory anaemia after Epo initiation
was 10 months (range: 7–54 months). Two cases had
been treated exclusively with epoietin-a, one solely
with epoietin-b and the two others with a combina-
tion of both. With ﬁve cases out of a total of about
2500 dialysis patients and 2300 Epo-treated dialysis
patients or an exposure rate to Epo of 9900 dialysis
patient-years during a 4.3 year period, this prevalence
is among the highest of those reported in European
countries.
Conclusions. The prevalence of PRCA after Epo
administration in dialysis patients appears particu-
larly high in Switzerland. Among the potential
explanations, the most plausible are the high percent-
age of dialysis patients treated with Epo, the almost
exclusive subcutaneous administration, the larger mar-
ket distribution of the epoietin-a brand, the eventual
disruption of the cold chain and the setting-up of a
systematic national survey.
Keywords: anti-erythropoietin antibodies; chronic
dialysis; chronic kidney failure; end-stage renal dis-
ease; erythropoietin; pure red-cell aplasia; renal
anaemia
Introduction
The gene for human erythropoietin (Epo) was cloned
and expressed in 1985 [1,2] and recombinant human
Epo was approved for marketing in 1987 in the United
States and in 1988 in Switzerland. During the 1990s,
despite the liberal use of Epo in clinical practice,
only three cases were reported worldwide in which
anti-Epo antibodies (Ab) were detected after Epo
administration [3–5].
However, in February 2002, Casadevall et al. [6]
published a series of 13 patients on chronic dialysis
who developed pure red-cell aplasia (PRCA) due to
neutralizing anti-Epo Ab while receiving Epo therapy.
By now, over 200 cases of PRCA occurring after
Epo administration have been reported, most often to
the manufacturers and/or health authorities [7–9].
The presence of anti-Epo Ab was not documented in
all of them. This occurrence has now led to impor-
tant changes in the determination of Epo type and
mode of administration (www.swissmedic.ch/cgi7news)
[10,11].
When the ﬁrst two cases were observed in
Switzerland by one of the authors (C.S.), the Swiss
Society of Nephrology asked through its Dialysis
Committee, with the help of the Swissmedic
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Pharmacovigilance Section, for the setting up of a sys-
tematic survey of the observed cases among dialysis
patients. We report here the results of this investigation.
Subjects and methods
A questionnaire was set up and sent in January 2003 to the
nephrologist in charge of each of the 69 dialysis units in
Switzerland (among which are three paediatric units). We
asked about the occurrence of past or present cases of
end-stage renal disease patients with suspected or proven
diagnosis of PRCA due to anti-Epo Ab. The period of
survey extended between 1998 and June 2002, since during
summer 2002, due to the occurrence of the syndrome,
important changes in Epo administration were introduced.
In addition, information on the number of patients treated
by dialysis at the end of 2002 was also requested. The dial-
ysis staffs of the centres that did not respond or returned
incomplete data were interviewed directly by telephone.
The clinical, diagnostic and therapeutic data of the
suspected cases were collected and compared with the
information already obtained by the Swissmedic Pharma-
covigilance Section and by the national branches of the
manufacturers. Only cases with positive anti-Epo Ab were
considered for analysis. The antibody tests had been
performed by either radioimmunoprecipitation or enzyme-
linked immunosorbent assays in different laboratories
(Service d’He´matologie Clinique, Hoˆpital Hoˆtel-Dieu, 75181
Paris, France; CLIA Laboratory, Immunochemistry Dept,
PPD Development, 2244 Dabney Road, Richmond, VA
23230, USA; MDS, Pharma Services, 2350 rue Cohen,
Saint-Laurent, Montreal, Quebec, H4R 2N6 Canada).
Just the Epo-a and -b brands were available during
the survey period, since darbepoietin only became available
in Switzerland in September 2002. According to different
sources, the a brand constituted 70% and the b brand 30%
of the total sales for dialysis patients during the observation
period.
Results
All the 69 Swiss dialysis centres participated in the
survey. A total of ﬁve cases of conﬁrmed PRCA with a
positive test for neutralizing anti-Epo Ab were identi-
ﬁed. Their characteristics and clinical evolution are
summarized in Table 1.
In addition to the positive anti-Epo Ab test, a bone
marrow biopsy was compatible with PRCA in all cases
and other causes of PRCA had been excluded on
clinical, biological and serological grounds. All were
treated by chronic haemodialysis for 9 months and
developed refractory anaemia after a median of 10
months (range: 7–54 months) of Epo therapy.
According to our information, only Epo-a had been
used in two cases, one patient had received Epo-b
exclusively and in the two remaining cases both a and b
brands had been administered. In those last two cases,
Epo-a had been given ﬁrst at doses increasing from
7500 to 12 000U/week for 2 and 5 months, respec-
tively, and then replaced by Epo-b at 7000 to
20 000U/week for 5 and 7 months, respectively,
before the diagnosis of PRCA was made.
The clinical evolution was interesting in several
aspects: in two cases a remission occurred sponta-
neously 3 and 6 months after Epo withdrawal with-
out any immunosuppressive therapy; in another case
PRCA persisted clinically after kidney transplantation,
requiring blood transfusions for 6 months, however,
the anti-Epo Ab are still positive, despite immunosup-
pressive therapy, 3 years after transplantation and 3.5
years after Epo withdrawal. Cases 2 and 3 are reported
in detail elsewhere [12,13].
Since all the dialysis units responded to this
survey, the prevalence of PRCA due to anti-Epo Ab
in Switzerland could be calculated. With 69 dialy-
sis units in a country of 7.3 million inhabitants,
Switzerland has a high density of dialysis centres.
During 2002, the incidence and prevalence of chronic
dialysis patients were 115 and 343 per million
inhabitants, respectively. According to our survey, at
the end of 2002, a total of 2555 patients were treated
by chronic dialysis: 2237 by haemodialysis (among
which 27 were haemodialyzed at home) and 318 by
peritoneal dialysis. These numbers had been increas-
ing only slowly over the preceding 4 years. This means
that with ﬁve cases for around 2500 dialysis patients,
Switzerland has a higher prevalence (1/500) than its
surrounding countries: France with 33 cases out of
28 000 chronic dialysis patients (1/848), Germany
with six out of 58 000 (1/9666) and Italy with four out
of 36 000 (1/9000) [8,14].
Those diverse prevalences can be explained, at
least partly, by the varying uses of Epo in the differ-
ent countries and their administration mode [10].
According to our survey, during the ﬁrst part of 2002,
90% of the total dialysis population was treated
with Epo, among which 79.4% were treated subcuta-
neously (s.c.) and 20.6% intravenously (i.v.). Based
on those results it appears that, when considering the
two Epo brands together, the ﬁve cases were observed
in a weighted chronic dialysis population of 2500, in
an Epo-treated dialysis population of around 2300
patients or in about 9900 dialysis patient-years of
exposure to Epo during a 4.3 year period. According to
various sources, during the survey period the a brand
constituted 70% of the sales to the chronic dialysis units
in Switzerland. When restricted to the pure cases, this
prevalence becomes 1/1150 for only Epo-a-treated
patients and 1/2300 for only Epo-b patients.
Discussion
The present survey identiﬁed ﬁve cases of PRCA
occurring during Epo therapy in chronic dialysis
patients in Switzerland. Some of our observations
shed additional light on the clinical evolution of
Epo-related PRCA: while, so far, a spontaneous
remission appears exceptional [8], in our cases 4 and 5,
a remission of the syndrome occurred spontaneously
without any immunosuppressive therapy, respectively,
2122 C. Scho¨nholzer et al.
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3 and 6 months after Epo withdrawal. In contrast,
while kidney transplantation is reported to cure PRCA
syndrome within a few weeks [6–8], in our case 2,
PRCA persisted clinically, necessitating blood transfu-
sions during 6 months after an otherwise successfully
functioning kidney transplant and the anti-Epo Ab
still remain positive 3 years after transplantation, with
haemoglobin levels oscillating spontaneously between
64 and 82 g/l [13].
The most interesting observation of this survey is
the high prevalence of PRCA due to anti-Epo
Ab observed in Switzerland: ﬁve cases for a chronic
dialysis population receiving Epo of 2300 and an
exposure rate of 9900 patient-years during a 4.3 year
period. Even if this total population remains low
when compared with other countries, it has to be
noted that in France, despite the initial report by
Casadevall et al. [6] and the subsequent increased
awareness, a lower prevalence is observed [10]. The
prevalence is also much lower in other neighbouring
countries, such as Germany and Italy. It is presently
estimated that the incidence of PRCA due to anti-Epo
Ab is one to two per 10 000 dialysis patients receiving
Epo by the s.c. route [11]. Due to the changes in
the manufacturing, handling and prescription mode
introduced for the Epo-a brand during summer 2002,
the occurrence of new cases seems to be decreasing.
The national discrepancies appear multifactorial.
In France, the patient has to go to the pharmacy in
person to obtain the product with a subsequent greater
risk of cold-chain disruption, while in Germany and
Italy, Epo is routinely administered by the dialysis staff
and much more often by the i.v. route. In Switzerland,
Epo is generally ordered and stocked directly by the
dialysis unit or hospital pharmacy and administered
most often s.c., directly by the dialysis staff.
Several factors can be put forward to explain the
high frequency of PRCA cases due to anti-Epo Ab
observed in Switzerland:
(i) Since in our country Epo was admitted and
reimbursed very early for chronic dialysis
patients, it could be prescribed without ﬁnancial
or administrative constraints, which explains
why 90% of chronic dialysis patients received
Epo.
(ii) On the basis of a national multicentre study
[15] and the, by then, existing guidelines [11],
s.c. administration was – until summer 2002 –
used in the vast majority of Swiss dialysis
patients (up to 94% in the Suisse romande
centres during a quality evaluation survey
conducted in 2001 in the 21 dialysis units of
western Switzerland [16]: 92.4% of
this chronic dialysis population (n¼ 617)
received Epo and among those, 94.4% received
Epo by the s.c. route); subsequently, this route
was demonstrated to put the patients at greater
risk of PRCA [8,11].
(iii) Among the two different brands of Epo avail-
able, the a formulation was used in almost 70%
of the Swiss patients during the observation
period. Since that time, the a brand has been
shown to represent a greater risk, which led the
manufacturer to forbid its s.c. use in December
2002 (www.swissmedic.ch/cgi7news).
(iv) The possibility of a ruptured cold-chain was
ﬁrst suggested by the fact that two of the ﬁve
cases were observed in the same dialysis centre,
but they occurred in a 2 year time interval and
the handling of the medication was repeatedly
investigated by the hospital pharmacist, who
ruled out this possibility; moreover, in none
of the ﬁve cases was self-administration prac-
tised at home, which makes this hypothesis
less likely.
It must also be added that due to the mandatory
declaration to Swiss health authorities of any clinical
syndrome suspected of PRCA during Epo admin-
istration and the simultaneous 100% response rate of
the present survey, the prevalence reported here
corresponds to the real prevalence, which is not
necessarily the case in other countries.
Indeed, a recent Editorial proposed the setting up
of a dedicated independent registry devoted to the
Epo-induced PRCA syndrome, in order to obtain a
clearer view of its occurrence and outcome [11]. Our
survey appears as an original step in this direction
and seems to indicate that the prevalence might be
underestimated at present.
In conclusion, the prevalence of PRCA after
Epo administration in dialysis patients appears partic-
ularly high in Switzerland. Among the potential
explanations, the most plausible are the large use of
Epo in dialysis patients, the almost exclusive s.c.
administration, the larger market distribution of the
Epo-a brand, the eventual disruption of the cold
chain and the setting up of a systematic national survey.
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